Chromocell Therapeutics (CHRO) Announces Amendment to Share Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Chromocell Announces Amendment to Stock Repurchase Plan
October 24, 2024 8:45 AM EDTFREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (Chromocell, or the Company), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the Board of Directors) has authorized an amendment (the Amendment) to the Companys existing stock repurchase plan (as amended, the Repurchase Plan) to increase the total value of shares of Chromocells common stock (Common Stock) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.
In addition, the Amendment extends the termination date of the... More
